|Board of Directors' Biographies|
President, Perfusion and Surgical Devices
Mr. Arik A. Anderson is currently the President of Perfusion and Surgical Devices for Terumo Cardiovascular. Mr. Anderson was Senior Vice President, R&D and Operations and General Manager for Somanetics from October of 2007 until the completion of the integration with Covidien in May of 2011. From July 2005 until joining Somanetics, Mr. Anderson served as Director of Product Development for Delphi Medical Systems, a provider of technology and products to the infusion, respiratory care, vital signs monitoring and power mobility medical device markets. He was in charge of a team of 45 engineers in the US, Mexico, and India who supported existing products and developed next generation products. From April 2004 until July 2005, Mr. Anderson was the President and Chief Executive Officer of Tasso Solutions, a product development and manufacturing consulting firm specializing in helping companies outsource design and manufacturing work. From December 2002 until April 2004, Mr. Anderson was the Vice President of Engineering Services for TriVirix International, a design and manufacturing services company focused specifically on the medical device industry, serving customers such as Johnson & Johnson and Medtronic. In this capacity, Mr. Anderson was in charge of 50 engineers for TriVirix in the US and Europe. Mr. Anderson received a Bachelor of Science degree in Electrical and Computer Engineering from the University of Wisconsin – Madison.
In his over 25 years of professional business expertise, Mr. Grogan has been an entrepreneur and an investment banker currently serving as the Managing Director for the Michigan Accelerator Fund I, a venture capital firm investing in Michigan-based, early stage companies. His investments are largely in the life sciences sector, both in devices and therapeutics. Mr. Grogan has raised over $25 million for start-up and early stage companies and has started and owned numerous businesses, including an NASD broker/dealer firm (Stanley Grogan Investments), several technology companies, and consulting firms focused on start-up businesses (Acuity Capital Management, Acuity Capital Partners). Mr. Grogan is a member of the Michigan Pre-Seed Investment Fund Investment Review Board, and he has judged the Great Lake Entrepreneurial Quest, the ACG Cup, and the ACE awards. Mr. Grogan also serves as the Chairman of nanoRETE, Inc. and as an Advisory Director for the Michigan Israeli Business Bridge. He attended Huntington College in Montgomery, AL, where he studied chemistry and biology and was granted early admission to the University of Alabama School of Optometry in Birmingham, AL, where he studied general optometry and physiological optics.
Michael Hagen - Chair
Michael currently works at Ash Stevens, Inc. as Director of Business Development. Ash Stevens, Inc. is a premier small molecule API contract manufacturer that is located in Riverview, Michigan. Prior to joining Ash Stevens, Inc., Michael was Director, Entrepreneurial Services-Biosciences for the Michigan Economic Development Corporation (MEDC), specializing in the biomedical market. In his role at the MEDC he was tasked with the operation of the Life Science Innovation Center in Plymouth, MI. This included assisting an array of companies ranging from start-up to established life science and medical device companies at MSLIC along with recruiting companies for that facility. Michael has worked in the life science industry for over 20 years with roles at both small startups to large companies such as Pall Corporation. In his role with Pall Corp. he was heading up life science divisions while living and working both in the continental U.S., Singapore, and Australia. Michael is a graduate from Michigan State University with a bachelor's of science in Microbiology.
Charles Hasemann, PhD
Charles A. Hasemann, PhD, Assistant Vice President for Innovation and Economic Development at the Michigan State University Innovation Center, earned his doctorate in Molecular Immunology and performed his post-doctoral training in X-ray Crystallography. As an Assistant Professor at UT Southwestern Medical Center in Dallas, he established an NIH-funded laboratory studying immune system-related protein structure and function. He was subsequently recruited to Parke-Davis Pharmaceuticals in Ann Arbor, MI (later merged with Pfizer, Inc) as the Director of structure-based drug design, and via a series of expanding management positions, ultimately joined the Executive Management team with direction over all aspects of drug discovery at the Ann Arbor site, as well as global leadership responsibilities for Pfizer’s overall drug discovery technologies. In his capacities at Pfizer, Dr. Hasemann oversaw several extensive and productive collaborations with biotechnology companies and academic laboratories. In his time at MSU, Dr. Hasemann has launched the Clinical & Translational Sciences Institute, Business-CONNECT, and most recently, Spartan Innovations. Dr. Hasemann now leads the MSU Innovation Center, consisting of Business-CONNECT, MSU Technologies, and Spartan Innovations; these three organizations comprise MSU’s effort to partner with the private sector in order to leverage the University’s intellectual assets for economic value. Combining his corporate research executive experience, with his academic research and administration experiences, Dr. Hasemann is well credentialed to lead the MSU Innovation Center on its mission to create productive research and technology commercialization relationships between MSU and the private sector, to connect regional entrepreneurs to the intellectual and technical capacity of the University, and to participate in regional economic activity endeavors.
President & CEO
In addition to his role with Esperion Therapeutics, Mr. Mayleben is also an advisor to, and investor in, life science and healthcare companies through his advisory and investment firms, ElMa Advisors and Esperance BioVentures. Prior, he served as President and Chief Operating Officer and Director of NightHawk Radiology Holdings, Inc. and Chief Operating Officer and Chief Financial Officer of Esperion Therapeutics, which later became a division of Pfizer Global Research & Development. While at Esperion, Mr. Mayleben led the raising of more than $200 million in venture capital and institutional equity funding and later negotiated the acquisition of Esperion by Pfizer in 2004 for $1.3 billion. He holds a master’s degree in business administration with distinction from the J.L. Kellogg Graduate School of Management at Northwestern University and a bachelor’s degree in business administration from the University of Michigan Ross Business School. Mr. Mayleben serves on the Advisory Board for the University of Michigan Wolverine Venture Fund and also as a director for several private life science companies.
Executive Director, Center for Entrepreneurship & Innovation
J. Kevin McCurren is the Executive Director for the Center for Entrepreneurship & Innovation at Grand Valley State University, Seidman College of Business. He has over 25 years of combined corporate and entrepreneurial experience. As an entrepreneur, he has been involved in the start‐up of a medical management company, a dental laboratory company, and several biomedical companies. As an investor, Kevin has been an angel investor for over 15 years and has involved in several angel investment groups. He has served on the Executive Committee of the Venture Club of Louisville, and has served on Board Committees of the Louisville Medical Center Development Corporation, MetaCyte Incubator, the Beargrass Endowment Fund, the Charter and Priority Health Care. Most recently, Kevin served as a start‐up executive with Intervention Insights, a Spark funded company and honoree of the 2011 50 Michigan Companies to Watch. Mr. McCurren was a co‐author of 2009 Empowering Entrepreneurship, a study of the entrepreneurship climate in West Michigan. A 2010 graduate of the Michigan Political Leadership Program, Mr. McCurren was the former Mayor of the City of Crossgate, KY, and founding chair of the Greater Grand Rapids Bicycle Coalition. Kevin holds a Bachelor of Science and Master’s Degree in Public Health and Health Services Management from the University of Missouri.
Kevin currently serves as Managing Director of the Michigan Medical Device Accelerator, a medical device idea accelerator that is focused on early stage investments. In this role, Kevin is responsible for the commercialization, financial management, intellectual property protection, talent acquisition, acceleration and operational administration of the Michigan Medical Device Accelerator. Kevin’s over 20 years of industry experience centers on Stryker Corporation, where he held a number of leadership roles during his 17 year career. His responsibilities included marketing, sales, business development, strategic planning, portfolio expansion and geographical market development. Beyond his domestic experience, Kevin has lived and worked extensively in European, Asian and Latin American markets building customer‐focused teams in order to drive market penetration. Kevin currently holds positions with the Michigan Medical Device Consortium, MichBio, Great Lakes Entrepreneurs Quest, ENT Biotech, Impact Athletic, NanoMag, and PRS Medical.
Finance Director, Enterprise Improvement
Mr. Morris currently serves as the global finance lead for Enterprise Improvement at renowned consulting firm AlixPartners. Prior to this, he was Director, Operations-Lumigen at Beckman Coulter. He was previously a Senior Manager in the Southfield office of Grant Thornton LLP and a member of the firm's national Life Sciences Steering Committee. Mr. Morris has worked in a variety of industry settings, primarily life sciences, and led several engagements for biotech and pharmaceutical clients related to operational improvements, finance and strategy. He holds an MBA from the Tuck School of Business at Dartmouth College and a BBA with First Class Honors from Brock University in St. Catharines, Ontario. In addition to MichBio, he serves on the Board of Vista Maria.
Assistant Director, Health Technologies
Ed Pagani, PhD, advises researchers at the University of Michigan School of Medicine to promote, protect and commercialize new discoveries in health technologies. Ed gained extensive licensing and R&D experience in the pharmaceutical and in vitro diagnostics industries as Assistant Director, Cardiopulmonary Pharmacology, at Sterling Winthrop; Senior Director, Strategic Alliance at Pfizer; and Vice President, Molecular Diagnostics, at Beckman Coulter. Prior to joining the Office of Technology Transfer in 2013, Ed held the position of CEO, North America at LGC, LTD, a private, equity-backed company headquartered in London, England. Ed holds an AB degree from Columbia University, a PhD in Physiology from the University of Cincinnati College of Medicine, and completed 3 years of post-doctoral training at Harvard Medical School/Brigham & Women's Hospital. He has over 55 scientific publications in peer-reviewed journals.
President & CEO
Dr. Rapundalo has broad experience in the life sciences with an extensive background in pharmaceutical research and development. Prior to his appointment as Executive Director of MichBio in April 2006, he spent almost 20 years as a senior research scientist, project manager, and group leader with Parke-Davis Pharmaceutical Research and then Pfizer, Inc., primarily in the area of cardiovascular drug discovery. In recent years, Dr. Rapundalo led a global interdisciplinary team that developed a strategic, operational, and organizational change management program to improve Pfizer's worldwide R&D business processes. He has a strong background in innovation and is an internationally recognized expert in a number of technology areas, including high-throughput screening and proteomics, among others. Dr. Rapundalo has a superb record of scientific achievement with over 50 publications, book chapters, and monographs. He has served as a peer-reviewer for a variety of prominent scientific journals and national funding agencies. In addition, he continues to be active in a broad range of industry and governmental initiatives, including intellectual property commercialization, talent recruitment and retention, science education, and economic development. Dr. Rapundalo has been a community advocate and civic leader for almost 20 years.
Physician & Former U.S. Representative
Since graduating from Battle Creek Central High School in 1955, U.S. Rep. Joe Schwarz has served his nation, his state, and his community. In 1986, Dr. Schwarz won a hotly contested race for the Michigan state Senate. He joined the chamber's leadership in 1993 as president pro tempore, a position he held for the next 10 years until term limits compelled his departure from the legislature at the end of 2002. As the state Senate's only physician, and as a member of the Health Policy Committee, Dr. Schwarz was the chamber's resident expert on health care issues. As chair of the Appropriations Subcommittee on Higher Education, Dr. Schwarz was, and remains, a forceful advocate for keeping the avenues of scientific and medical research open to students and scientists. While serving as chairman of the subcommittee, Dr. Schwarz made sure public colleges and universities received adequate state funding, helping keep education accessible to Michigan residents.
David Serota, PhD DABT
David G. Serota, PhD, DABT, is Senior Vice President of Drug Safety, Senior Principal Study Director, and joined MPI Research in March 1997. In this capacity, he oversees all general toxicology, infusion, developmental and reproduction, safety pharmacology, neurobehavioral, PK, ADME, experimental therapeutics, and surgical studies conducted at MPI Research, and manages a staff of approximately 80, including 45 Study Directors and 15 anatomic and clinical pathologists. Dr. Serota has more than 36 years of experience as a toxicologist in the contract toxicology industry, having previously served as Director of Toxicology at Southern Research Institute and as Director of Laboratory Operations and Senior Toxicologist at Hazleton Laboratories Vienna (now Covance) for 15 years. He received a BS in pharmacy in 1969 from Auburn University and a PhD in 1976 in toxicology from the University of Tennessee. Dr. Serota is a Diplomate of the American Board of Toxicology and a member of both the Society of Toxicology and the American College of Toxicology. He recently completed a one-year term as President of the American College of Toxicology and this year he is serving as Past President and Chairman of both the Nominations and the Outreach Committees.
Vice President, Economic Development
Mr. Staebler’s charge is to leverage Wayne State’s assets to be a catalyst for growth across the university and the community. His responsibilities include coordinating the university’s activities around innovation and entrepreneurship, the commercialization of university intellectual property, and business development, and attraction. Prior to joining Wayne State University, Mr. Staebler served as the vice president for Entrepreneurial and Capital Services at the Michigan Economic Development Corporation. In this role, he was responsible for the oversight of the Michigan Strategic Fund Board and the 21st Century Jobs Fund. As part of these efforts, he led the investment and management of $600 million of state funds into entrepreneurial companies, venture capital and private equity funds, and strategic service providers. Previously, Mr. Staebler spent nearly a decade in the private sector, working in both start-up and Fortune 150 environments where he served on the management team of the Helios Group, a technology-based financial services start-up. After Helios was acquired in 2000, he spent the next three years in the company’s London, England, office as an associate director. Mr. Staebler is a graduate of the University of Detroit Jesuit High School and Harvard College, and he received a master’s degree from the London School of Economics and Political Science. In addition, Mr. Staebler serves on various boards, including TechTown; NextEnergy; Midtown Detroit, Inc.; the Ann Arbor Local Development Finance Authority; and the Ann Arbor Housing and Human Services Advisory Board.
EVP & COO
Mr. Stein, a graduate of Eastern Michigan University, has spent the entirety of his 20-year professional career in the health care industry. He began by working in the clinical laboratory and advanced through positions in diagnostic product sales/marketing to roles in quality management, validation engineering, product development, project management, and executive management in the pharmaceutical industry. As senior vice president of the Ferndale Pharma Group, Inc., Mr. Stein is responsible for in-licensing, out-licensing, M&A activities, overseeing due diligence activities, and project management for all of the group’s operating companies which consists of Ferndale Healthcare Inc., specializing in prescription topical drugs, Biopelle, Inc. focusing on aesthetic product marketing, Eloquest Healthcare, Inc., a hospital specialty company, and Ferndale Contract Manufacturing, Inc.
Chief of Radiation Biology
Scientific Director of the Beaumont Biobank
Born in Edinburgh, Scotland, Dr. Wilson received his PhD from the University of Liverpool in the UK in 1978 and undertook his postdoctoral training at the Universities of Birmingham and London. In 1984, Dr. Wilson joined the Gray Laboratory in London as a senior scientist and worked there for 18 years. In 2002, he became Professor of Radiation Oncology at Wayne State University and the Karmanos Cancer institute. Dr. Wilson joined Beaumont in 2005 as Chief of Radiation Biology. In 2008, he also became the Scientific Director of the Beaumont BioBank and the Director of the Erb Family Core Molecular Laboratory at Beaumont Research Institute. Dr. Wilson has published over 190 scientific articles and book chapters. Dr. Wilson received the Beaumont Physicians 2013 Outstanding Doctor "Seeker of Truth” award for research.
by delivering business-critical resources & bottom line savings
by connecting Michigan's bio-industry one member at a time
by influencing business growth through advocacy
by creating opportunities that develop people & build organizations